SABCS 2022

HR-Positive/HER2-Negative Breast Cancer

Patient-Reported Outcomes and Progression-Free Survival Findings from the 5th Interim Analysis of the RIBANNA Trial in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer

SABCS 2022

Interim analysis of the RIBANNA trial demonstrates that ribociclib provides a meaningful PFS benefit and maintains QOL in patients with HR-positive/HER2-negative advanced breast cancer. Read More ›

HR-Positive/HER2-Negative Breast Cancer

Pooled Analysis of Post-Progression Treatments after Ribociclib in the MONALEESA-2, -3, and -7 Trials in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer

SABCS 2022

Post-progression targeted therapy after ribociclib found to result in increased duration of therapy. Read More ›

HR-Positive/HER2-Negative Breast Cancer

Ribociclib-Derived Resistance Mutations: ctDNA Findings from the MONALEESA-2, -3, and -7 Trials

SABCS 2022

Comprehensive analysis of acquired resistance mutations in patients with HR-positive/HER2-negative advanced breast cancer post-CDK4/6 inhibitor and endocrine therapy is the largest to date. Read More ›

HR-Positive/HER2-Negative Breast Cancer

Pooled Analysis of Gene Expression and Associated Treatment Response in the MONALEESA-2, -3, and -7 Trials

SABCS 2022

Results from the MONALEESA trials show that PFS benefit with ribociclib in combination with endocrine therapy found to be consistent regardless of expression levels of most cell cycle genes. Read More ›

HR-Positive/HER2-Negative Breast Cancer

Comparison of Progression-Free Survival from the MONALEESA and RIBANNA Trials in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer

SABCS 2022

Analysis from the MONALEESA and RIBANNA trials in patients with HR-positive/HER2-negative advanced breast cancer finds differences in PFS among patients treated with ribociclib in combination with endocrine therapy among MONALEESA-like subgroups. Read More ›

SABCS 2022

Page 2 of 2